CANCER CENTER

基督教青年会请求继续支持与赠款有关的活动， 包括9个共享资源，14个已建立的研究项目，1个正在开发中 计划和新的临床试验方案审查和开发系统。 这些项目在四名助理的指导下管理 董事，与董事和一名联营公司共同工作 主任和他的行政人员在四个领域：基础科学， 临床科学、癌症预防研究和社区研究。 教育署副署长负责监督教育及培训工作 该中心的项目。我们请求继续支持这位资深人士 领导力和既定研究计划的领导者，用于规划和 评估、发展基金和管理。 临床领域的跨学科协调是由 以疾病为导向的单元在乳腺癌、胃肠道癌、胃肠道癌和头颈癌中的应用； 黑色素瘤、淋巴瘤、脑瘤和骨髓支持单位 移植。耶鲁大学在分子生物学方面的非凡深度提供了 专注于中心的翻译研究。临床研究 课程围绕主要专业进行组织，并已在 这一赠款周期扩大了对使用新技术的重视，以 克服癌症治疗和预防的主要局限性 通过共享资源(以前称为组织)的方式进行转移 检索资源，现在的关键技术共享资源， 将尖端分子技术纳入临床的能力 诊断、治疗和预防方面的试验，以允许适当的 组织的保存，结构和功能的测量 与结果相关联。自上次授予以来的新共享资源 临床药理学利用YCCC的优势 癌症药理学。其他共享资源包括，流式细胞术， 动物肿瘤模型，组织培养/基质制备，质谱学， 铯-13T照射器和转基因小鼠共享资源。这个 病理学、分子肿瘤学和发展的基础研究项目， 分子病毒学和细胞生物学都强调对癌基因的研究 以及抑制癌基因与细胞信号系统的关系。这个 免疫学计划侧重于抗原的调节和生长控制 由T细胞处理。发育治疗学？化疗 该计划旨在开发针对新发现的抗癌药物 分子靶标。一项正在开发的癌症遗传学项目将尝试 将这些活动转化为临床有用的工具。

The YCCC requests continued support for grant related activities that include 9 shared resources, 14 established research programs, 1 developing program and a new clinical trials protocol review and development system. These programs are managed under the direction of four associate directors, working in conjunction with the Director, and an Associate Director, and his administrative staff in four areas: Basic Science, Clinical Science, and Cancer Prevention Research, and Community Research. An Associate Director of Education oversees the Education and training programs of the center. We request continued support for this senior leadership and leaders of established research programs, for planning and evaluation, and developmental funds, and administration. Interdisciplinary coordination in the clinical areas is facilitated by the use of disease oriented units in Breast, GU, GI and Head and Neck cancers; Melanoma, Lymphomas, Brain tumor and a support unit on bone marrow transplantation. Yale's extraordinary depth in Molecular Biology provides focus for the centers translational research. The clinical Research programs are organized around major specialties and have been augmented in this grant cycle by an expanded emphasis on the use of new technology to overcome the major limitations of cancer treatment and prevention by transferring through the means of a shared resource, formerly the tissue retrieval resource, and now the Critical technologies Shared Resource, the capability to include sophisticated molecular technologies in clinical trials in diagnosis, treatment and Prevention, to allow the proper preservation of tissue, and the measurement of both structure and function to correlate with outcome. A new shared resource since the last grant cycle, Clinical Pharmacology, takes advantage of the YCCC's strength in Cancer Pharmacology. Other shared resources include, Flow Cytometry, Animal Tumor Models, Tissue Culture/Media Preparation, Mass Spectrometry, a Cesium-13T Irradiator, and a Transgenic Mouse Shared Resource. The basic research programs in Pathology, Molecular Oncology and Development, Molecular Virology and Cell Biology all emphasize research on oncogenes and suppressor oncogenes vis-a-vis the cell signaling systems. The Program in Immunology focuses on regulation of antigen and growth control processing by T-cells. The Developmental Therapeutics?Chemotherapy Program aims at developing anticancer agents directed at newly identified molecular targets. A developing program in Cancer Genetics will attempt to translate these activities into clinically useful tools.